At a time when the use of laughing gas (nitrous oxide) in clinical practice has gradually reduced, a new article contends that there is 'no clinically relevant evidence' for the withdrawal of nitrous oxide.
The issue whether laughing gas (nitrous oxide) should be banned from the operating room figured prominently in a debate at this year's Euroanaesthesia meeting in Berlin.
"Whereas 30 years ago, nearly every general anaesthesia procedure was performed with nitrous oxide as an adjuvant, a steady decline of its use over the last 15 years has been observed. There are several reasons, which caused the reduction of the usage of nitrous oxide," said Professor Rolf Rossaint from the University Hospital Aachen, Germany, who is in favour of nitrous oxide ban.
Countering his views, Professor Daniel Sessler, Cleveland Clinic, Ohio, US, in his talk on "nitrous oxide is an effective and safe anaesthetic" put forward arguments against a ban.
"There is ... no compelling evidence that nitrous oxide causes important clinical complications. In fact, large randomised trials consistently show that nitrous oxide does not promote complications," Sessler said.
"Nitrous oxide is inexpensive and has favourable kinetics; it does not increase the risk of surgical site infection, post-operative myocardial infarction, or cancer recurrence. And the two complications resulting from nitrous oxide administration, nausea and bowel distension, are minor and no worse than complications caused by alternative anaesthetics," Sessler added.
"There is no clinically relevant evidence for the withdrawal of nitrous oxide from the armamentarium of anaesthesia practice or procedural sedation," said the article published in the European Journal of Anaesthesiology.
The debate coincided with the article published in the European Journal of Anaesthesiology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
